CoChat
Sign Up
Cited by 3Lipoproteins and Cardiovascular HealthPharmacogenetics and Drug MetabolismPharmacovigilance and Adverse Drug Reactions

Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications

Open access
Spanakis, Marios, Alon-Ellenbogen, Danny, Ioannou, Petros, Spernovasilis, Nikolaos·2023·Pharmacy
DOI 10.3390/pharmacy11040130PMC PMC10457919
Open this paper in CoChat — free accountOpen PDF

Abstract

Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug–drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmacy11040130

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other medication classes often encountered in oral surgery patients that may increase DDI risk include antidiabetic drugs such as GLP-1 agonists and SGLT2 inhibitors, statins, antiepileptics, and antiresorptive osteoporosis drugs associated with medication-related osteonecrosis of the jaw.

    “Other medication classes often encountered in oral surgery patients that may increase the risk of DDI include antidiabetic drugs (such as GLP-1 agonists and SGLT2 inhibitors) [13], statins [14], antiepileptics [15,16] and antiresorptive osteoporosis drugs, which are associated with medication-related osteonecrosis of the jaw (MRONJ) [17][18][19][20].”

    From Comparing Artificial Intelligence (ChatGPT, Gemini, DeepSeek) and Oral Surgeons in Detecting Clinically Relevant Drug–Drug Interactions in Dental Therapy (2025) · cites this paper as [14]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 83

  1. [2]Marengoni A. Onder G. Guidelines, Polypharmacy, and Drug-Drug Interactions in Patients with Multimorbidity BMJ 2015 350 h1059 10.1136/bmj.h1059 25761379 · DOI
  2. [3]Masnoon N. Shakib S. Kalisch-Ellett L. Caughey G.E. What Is Polypharmacy? A Systematic Review of Definitions BMC Geriatr. 2017 17 230 10.1186/s12877-017-0621-2 29017448 PMC5635569 · DOI
  3. [4]Scheife R.T. Hines L.E. Boyce R.D. Chung S.P. Momper J.D. Sommer C.D. Abernethy D.R. Horn J.R. Sklar S.J. Wong S.K. Consensus Recommendations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support Drug Saf. 2015 38 197 206 10.1007/s40264-014-0262-8 25556085 PMC4624322 · DOI
  4. [5]Eyler R.F. Shvets K. Clinical Pharmacology of Antibiotics Clin. J. Am. Soc. Nephrol. 2019 14 1080 1090 10.2215/CJN.08140718 30862698 PMC6625637 · DOI
  5. [6]Leekha S. Terrell C.L. Edson R.S. General Principles of Antimicrobial Therapy Mayo Clin. Proc. 2011 86 156 167 10.4065/mcp.2010.0639 21282489 PMC3031442 · DOI
  6. [7]Calhoun C. Wermuth H.R. Hall G.A. Antibiotics StatPearls Orlando, FL, USA 2022 30571064
  7. [8]Roberts S.C. Zembower T.R. Global Increases in Antibiotic Consumption: A Concerning Trend for WHO Targets Lancet Infect. Dis. 2021 21 10 11 10.1016/S1473-3099(20)30456-4 32717207 · DOI
  8. [9]Spernovasilis N. Ierodiakonou D. Spanias C. Mathioudaki A. Ioannou P. Petrakis E.C. Kofteridis D.P. Doctors’ Perceptions, Attitudes and Practices towards the Management of Multidrug-Resistant Organism Infections after the Implementation of an Antimicrobial Stewardship Programme during the COVID-19 Pandemic Trop. Med. Infect. Dis. 2021 6 20 10.3390/tropicalmed6010020 33562723 PMC7930958 · DOI
  9. [11]Allel K. Day L. Hamilton A. Lin L. Furuya-Kanamori L. Moore C.E. Van Boeckel T. Laxminarayan R. Yakob L. Global Antimicrobial-Resistance Drivers: An Ecological Country-Level Study at the Human–Animal Interface Lancet Planet. Health 2023 7 e291 e303 10.1016/S2542-5196(23)00026-8 37019570 · DOI
  10. [12]Omar M.A. Wilson J.P. FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis Ann. Pharmacother. 2002 36 288 295 10.1345/aph.1A289 11847951 · DOI · Paper page
  11. [13]Anrys P. Petit A.E. Thevelin S. Sallevelt B. Drenth C. Soiza R.L. Correa-Pérez A. Dalleur O. De Brauwer I. Petrovic M. An International Consensus List of Potentially Clinically Significant Drug-Drug Interactions in Older People J. Am. Med. Dir. Assoc. 2021 22 2121 2133.e24 10.1016/j.jamda.2021.03.019 33901428 · DOI
  12. [14]Aronson J.K. Classifying Drug Interactions Br. J. Clin. Pharmacol. 2004 58 343 344 10.1111/j.1365-2125.2004.02244.x 15373925 PMC1884601 · DOI
  13. [15]Niu J. Straubinger R.M. Mager D.E. Pharmacodynamic Drug-Drug Interactions Clin. Pharmacol. Ther. 2019 105 1395 10.1002/cpt.1434 30912119 PMC6529235 · DOI
  14. [16]Yu J. Petrie I.D. Levy R.H. Ragueneau-Majlessi I. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017 Drug Metab. Dispos. 2019 47 135 144 10.1124/dmd.118.084905 30442649 · DOI
  15. [17]Kalliokoski A. Niemi M. Impact of OATP Transporters on Pharmacokinetics Br. J. Pharmacol. 2009 158 693 705 10.1111/j.1476-5381.2009.00430.x 19785645 PMC2765590 · DOI
  16. [18]Rimac H. Dufour C. Debeljak Ž. Zorc B. Bojić M. Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin Molecules 2017 22 1153 10.3390/molecules22071153 28696372 PMC6152318 · DOI
  17. [19]Eyal S. Hsiao P. Unadkat J.D. Drug Interactions at the Blood-Brain Barrier: Fact or Fantasy? Pharmacol. Ther. 2009 123 80 104 10.1016/j.pharmthera.2009.03.017 19393264 PMC2751796 · DOI
  18. [20]Zanger U.M. Schwab M. Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation Pharmacol. Ther. 2013 138 103 141 10.1016/j.pharmthera.2012.12.007 23333322 · DOI · Paper page
  19. [21]Jancova P. Anzenbacher P. Anzenbacherova E. Phase II Drug Metabolizing Enzymes Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2010 154 103 116 10.5507/bp.2010.017 20668491 · DOI
  20. [22]Zhang J. Sun Y. Wang R. Zhang J. Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin Sci. Rep. 2019 9 16194 10.1038/s41598-019-52632-5 31700098 PMC6838174 · DOI
  21. [23]Yoo H.H. Kim I.S. Yoo D.H. Kim D.H. Effects of Orally Administered Antibiotics on the Bioavailability of Amlodipine: Gut Microbiota-Mediated Drug Interaction J. Hypertens. 2016 34 156 162 10.1097/HJH.0000000000000773 26630218 · DOI
  22. [25]Spanakis M. Sfakianakis S. Kallergis G. Spanakis E.G. Sakkalis V. PharmActa: Personalized Pharmaceutical Care EHealth Platform for Patients and Pharmacists J. Biomed. Inform. 2019 100 103336 10.1016/j.jbi.2019.103336 31689550 · DOI
  23. [26]Spanakis M. Ioannou P. Tzalis S. Papakosta V. Patelarou E. Tzanakis N. Patelarou A. Kofteridis D.P. Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece J. Clin. Med. 2022 11 7172 10.3390/jcm11237172 36498745 PMC9740400 · DOI
  24. [27]Spanakis M. Ioannou P. Tzalis S. Chouzouri F. Patelarou E. Kofteridis D.P. Antoniou K.M. Schiza S.E. Patelarou A. Tzanakis N. Evaluation of Drug Interactions in Hospitalized Patients with Respiratory Disorders in Greece Adv. Respir. Med. 2023 91 74 92 10.3390/arm91010008 36825942 PMC9952796 · DOI
  25. [28]Spernovasilis N. Agouridis A.P. Tsioutis C. Appropriate Antimicrobial Use during the COVID-19 Pandemic: Not Cause for Complacency Lancet Microbe 2023 4 e293 10.1016/S2666-5247(23)00061-7 36933564 PMC10017110 · DOI
  26. [29]Blais J.E. Wei Y. Yap K.K. Alwafi H. Ma T.T. Brauer R. Lau W.C. Man K.K. Siu C.W. Tan K.C. Trends in Lipid-Modifying Agent Use in 83 Countries Atherosclerosis 2021 328 44 51 10.1016/j.atherosclerosis.2021.05.016 34091069 · DOI
  27. [30]Stergiou G.S. Ntineri A. Menti A. Kalpourtzi N. Vlachopoulos C. Liberopoulos E.N. Rallidis L. Richter D. Gavana M. Vantarakis A. Twenty-First Century Epidemiology of Dyslipidemia in Greece: EMENO National Epidemiological Study Hell. J. Cardiol. 2023 69 1 8 10.1016/j.hjc.2022.10.002 36243397 · DOI
  28. [31]Barter P.J. Rye K.A. New Era of Lipid-Lowering Drugs Pharmacol. Rev. 2016 68 458 10.1124/pr.115.012203 26983688 PMC4813424 · DOI
  29. [32]Kitzmiller J.P. Mikulik E.B. Dauki A.M. Murkherjee C. Luzum J.A. Pharmacogenomics of Statins: Understanding Susceptibility to Adverse Effects Pharmgenomics. Pers. Med. 2016 9 97 106 10.2147/PGPM.S86013 27757045 PMC5055044 · DOI
  30. [33]Vassy J.L. Michael Gaziano J. Green R.C. Ferguson R.E. Advani S. Miller S.J. Chun S. Hage A.K. Seo S.J. Majahalme N. Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol a Randomized Clinical Trial JAMA Netw. Open 2020 3 e2027092 10.1001/jamanetworkopen.2020.27092 33270123 PMC7716196 · DOI
  31. [34]Estudante M. Morais J.G. Soveral G. Benet L.Z. Intestinal Drug Transporters: An Overview Adv. Drug Deliv. Rev. 2013 65 1340 1356 10.1016/j.addr.2012.09.042 23041352 · DOI
  32. [35]Link E. Parish S. Armitage J. Bowman L. Heath S. Matsuda F. Gut I. Lathrop M. Collins R. SLCO1B1Variants and Statin-Induced Myopathy—A Genomewide Study N. Engl. J. Med. 2008 359 789 799 10.1056/nejmoa0801936 18650507 · DOI · Paper page
  33. [36]Turongkaravee S. Jittikoon J. Lukkunaprasit T. Sangroongruangsri S. Chaikledkaew U. Thakkinstian A. A Systematic Review and Meta-Analysis of Genotype-Based and Individualized Data Analysis of SLCO1B1 Gene and Statin-Induced Myopathy Pharmacogenomics J. 2021 21 296 307 10.1038/s41397-021-00208-w 33608664 PMC8159730 · DOI
  34. [38]Palleria C. Di Paolo A. Giofrè C. Caglioti C. Leuzzi G. Siniscalchi A. De Sarro G. Gallelli L. Pharmacokinetic Drug-Drug Interaction and Their Implication in Clinical Management J. Res. Med. Sci. 2013 18 600 609 PMC3897029 24516494
  35. [39]Price G. Patel D.A. Drug Bioavailability xPharm: The Comprehensive Pharmacology Reference Elsevier Boston, MA, USA 2022 1 2 10.1016/B978-008055232-3.60035-2 · DOI
  36. [40]Chong P.H. Seeger J.D. Franklin C. Clinically Relevant Differences between the Statins: Implications for Therapeutic Selection Am. J. Med. 2001 111 390 400 10.1016/S0002-9343(01)00870-1 11583643 · DOI
  37. [41]Di Stasi S.L. MacLeod T.D. Winters J.D. Binder-Macleod S.A. Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists Phys. Ther. 2010 90 1530 1542 10.2522/ptj.20090251 20688875 PMC2949584 · DOI
  38. [42]Hylton Gravatt L.A. Flurie R.W. Lajthia E. Dixon D.L. Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions Curr. Atheroscler. Rep. 2017 19 46 10.1007/s11883-017-0682-x 28990114 · DOI
  39. [43]Patel A.M. Shariff S. Bailey D.G. Juurlink D.N. Gandhi S. Mamdani M. Gomes T. Fleet J. Hwang Y.J. Garg A.X. Statin Toxicity from Macrolide Antibiotic Coprescription Ann. Intern. Med. 2013 158 869 876 10.7326/0003-4819-158-12-201306180-00004 23778904 · DOI
  40. [44]Hougaard Christensen M.M. Bruun Haastrup M. Øhlenschlæger T. Esbech P. Arnspang Pedersen S. Bach Dunvald A.C. Bjerregaard Stage T. Pilsgaard Henriksen D. Thestrup Pedersen A.J. Interaction Potential between Clarithromycin and Individual Statins—A Systematic Review Basic Clin. Pharmacol. Toxicol. 2020 126 307 317 10.1111/bcpt.13343 31628882 · DOI
  41. [45]Abu Mellal A. Hussain N. Said A.S. The Clinical Significance of Statins-Macrolides Interaction: Comprehensive Review of in Vivo Studies, Case Reports, and Population Studies Ther. Clin. Risk Manag. 2019 15 921 936 10.2147/TCRM.S214938 31413581 PMC6661989 · DOI
  42. [46]Goldie F.C. Brogan A. Boyle J.G. Ciprofloxacin and Statin Interaction: A Cautionary Tale of Rhabdomyolysis BMJ Case Rep. 2016 2016 48 10.1136/bcr-2016-216048 27469384 PMC4986139 · DOI
  43. [47]Fu Y. Yi Y. Fan Y. Shang R. Cytochrome P450 Inhibition Potential and Initial Genotoxic Evaluation of 14-O-[(4,6-Diaminopyrimidine-2-Yl)Thioacetyl] Mutilin Sci. Rep. 2020 10 13474 10.1038/s41598-020-70400-8 32778735 PMC7417534 · DOI
  44. [48]José M. Elisa G.-V. Jordi V. Macrólidos, Cetólidos y Estreptograminas Enferm. Infecc. Microbiol. Clin. 2003 21 200 208 10.1016/S0213-005X(03)72918-8 12681133 · DOI
  45. [49]Dare R.K. Tewell C. Harris B. Wright P.W. Van Driest S.L. Farber-Eger E. Nelson G.E. Talbot T.R. Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy Clin. Infect. Dis. 2018 67 1356 1363 10.1093/cid/ciy287 29668884 PMC6186852 · DOI
  46. [50]Golightly L.K. Barber G.R. Barron M.A. Page R.L. Statins and Daptomycin: Safety Assessment of Concurrent Use and Evaluation of Drug Interaction Liability Drug Metabol. Drug Interact. 2013 28 49 58 10.1515/dmdi-2012-0033 23314530 · DOI
  47. [51]Jones M.R. Urits I. Wolf J. Corrigan D. Colburn L. Peterson E. Williamson A. Viswanath O. Drug-Induced Peripheral Neuropathy: A Narrative Review Curr. Clin. Pharmacol. 2020 15 38 10.2174/1574884714666190121154813 30666914 PMC7365998 · DOI
  48. [52]Green S. Holton A. Drug-Induced Peripheral Neuropathy Advers. Drug React. Bull. 2016 300 1159 1162 10.1097/FAD.0000000000000020 · DOI
  49. [53]Vilholm O.J. Christensen A.A. Zedan A.H. Itani M. Drug-Induced Peripheral Neuropathy Basic Clin. Pharmacol. Toxicol. 2014 115 185 192 10.1111/bcpt.12261 24786912 · DOI
  50. [54]Wysocki J. Belowski D. Kalina M. Kochanski L. Okopien B. Kalina Z. Effects of Micronized Fenofibrate on Insulin Resistance in Patients with Metabolic Syndrome Int. J. Clin. Pharmacol. Ther. 2004 42 212 217 10.5414/CPP42212 15124979 · DOI
  51. [55]Miller D.B. Spence J.D. Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) Clin. Pharmacokinet. 1998 34 155 162 10.2165/00003088-199834020-00003 9515185 · DOI
  52. [56]Bays H.E. Dujovne C.A. Drug Interactions of Lipid-Altering Drugs Drug Saf. 1998 19 355 371 10.2165/00002018-199819050-00003 9825949 · DOI
  53. [57]Gallo D.G. Bailey K.R. Sheffner A.L. The Interaction between Cholestyramine and Drugs Proc. Soc. Exp. Biol. Med. 1965 120 60 65 10.3181/00379727-120-30443 5852732 · DOI
  54. [59]Morley V.J. Kinnear C.L. Sim D.G. Olson S.N. Jackson L.M. Hansen E. Usher G.A. Showalter S.A. Pai M.P. Woods R.J. An Adjunctive Therapy Administered with an Antibiotic Prevents Enrichment of Antibiotic-Resistant Clones of a Colonizing Opportunistic Pathogen Elife 2020 9 e58147 10.7554/eLife.58147 33258450 PMC7707840 · DOI
  55. [60]Phan B.A.P. Dayspring T.D. Toth P.P. Ezetimibe Therapy: Mechanism of Action and Clinical Update Vasc. Health Risk Manag. 2012 8 415 10.2147/VHRM.S33664 22910633 PMC3402055 · DOI
  56. [61]Kosoglou T. Statkevich P. Johnson-Levonas A.O. Paolini J.F. Bergman A.J. Alton K.B. Ezetimibe: A Review of Its Metabolism, Pharmacokinetics and Drug Interactions Clin. Pharmacokinet. 2005 44 467 494 10.2165/00003088-200544050-00002 15871634 · DOI
  57. [62]Matsuhashi H. Onodera S. Kawamura Y. Hasebe N. Kohmura C. Yamashita H. Tobise K. Probucol-Induced QT Prolongation and Torsades de Pointes Jpn. J. Med. 1989 28 612 615 10.2169/internalmedicine1962.28.612 2585889 · DOI
  58. [63]Briasoulis A. Agarwal V. Pierce W.J. QT Prolongation and Torsade de Pointes Induced by Fluoroquinolones: Infrequent Side Effects from Commonly Used Medications Cardiology 2011 120 103 110 10.1159/000334441 22156660 · DOI
  59. [64]Massaro M. Scoditti E. Carluccio M.A. De Caterina R. Nutraceuticals and Prevention of Atherosclerosis: Focus on Omega-3 Polyunsaturated Fatty Acids and Mediterranean Diet Polyphenols Cardiovasc. Ther. 2010 28 e13 e19 10.1111/j.1755-5922.2010.00211.x 20633019 · DOI
  60. [65]Spanakis M. Patelarou E. Patelarou A. Drug-Food Interactions with a Focus on Mediterranean Diet Appl. Sci. 2022 12 10207 10.3390/app122010207 · DOI
  61. [66]Kim K. Ginsberg H.N. Choi S.H. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins Diabetes Metab. J. 2022 46 517 532 10.4093/dmj.2022.0198 35929170 PMC9353557 · DOI
  62. [69]Ballantyne C.M. Bays H. Catapano A.L. Goldberg A. Ray K.K. Saseen J.J. Role of Bempedoic Acid in Clinical Practice Cardiovasc. Drugs Ther. 2021 35 853 10.1007/s10557-021-07147-5 33818688 PMC8266788 · DOI
  63. [70]Maxwell S.R.J. Evidence Based Prescribing: Is the Goal, but Prescribers Still Need Education, Experience, and Common Sense BMJ 2005 331 247 10.1136/bmj.331.7511.247 16051992 PMC1181254 · DOI
  64. [73]Wiggins B.S. Saseen J.J. Page R.L. Reed B.N. Sneed K. Kostis J.B. Lanfear D. Virani S. Morris P.B. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association Circulation 2016 134 e468 e495 10.1161/CIR.0000000000000456 27754879 · DOI
  65. [74]Williams D. Feely J. Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors Clin. Pharmacokinet. 2002 41 343 370 10.2165/00003088-200241050-00003 12036392 · DOI
  66. [75]Eljaaly K. Alshehri S. Bhattacharjee S. Al-Tawfiq J.A. Patanwala A.E. Contraindicated Drug-Drug Interactions Associated with Oral Antimicrobial Agents Prescribed in the Ambulatory Care Setting in the United States Clin. Microbiol. Infect. 2019 25 620 622 10.1016/j.cmi.2018.08.002 30107284 · DOI
  67. [77]Gilad R. Lampl Y. Rhabdomyolysis Induced by Simvastatin and Ketoconazole Treatment Clin. Neuropharmacol. 1999 22 295 297 10516882
  68. [78]Gupta A.K. Versteeg S.G. Shear N.H. Common Drug-Drug Interactions in Antifungal Treatments for Superficial Fungal Infections Expert Opin. Drug Metab. Toxicol. 2018 14 387 398 10.1080/17425255.2018.1461834 29633864 · DOI
  69. [79]Kyrklund C. Backman J.T. Kivistö K.T. Neuvonen M. Laitila J. Neuvonen P.J. Rifampin Greatly Reduces Plasma Simvastatin and Simvastatin Acid Concentrations Clin. Pharmacol. Ther. 2000 68 592 597 10.1067/mcp.2000.111414 11180018 · DOI
  70. [80]Baciewicz A.M. Chrisman C.R. Finch C.K. Self T.H. Update on Rifampin, Rifabutin, and Rifapentine Drug Interactions Curr. Med. Res. Opin. 2013 29 1 12 10.1185/03007995.2012.747952 23136913 · DOI
  71. [82]Yip D.W. Gerriets V. Penicillin Drug Allergy Test Elsevier Boston, MA, USA 2022 103 113 10.1016/B978-0-323-48551-7.00010-9 · DOI
  72. [83]Kemnic T.R. Coleman M. Trimethoprim Sulfamethoxazole Mayo Clin. Proc. 2022 74 730 734 10.4065/74.7.730 10405706 · DOI
  73. [84]Luft F.C. Aminoglycoside Interactions with Other Drugs Nephrotoxic Mech. Drugs Environ. Toxins 1982 135 150 10.1007/978-1-4684-4214-4_13 · DOI
  74. [85]Strandell J. Bate A. Hägg S. Edwards I.R. Rhabdomyolysis a Result of Azithromycin and Statins: An Unrecognized Interaction Br. J. Clin. Pharmacol. 2009 68 427 434 10.1111/j.1365-2125.2009.03473.x 19740401 PMC2766483 · DOI
  75. [86]Matsubara A. Oda S. Akai S. Tsuneyama K. Yokoi T. Establishment of a Drug-Induced Rhabdomyolysis Mouse Model by Co-Administration of Ciprofloxacin and Atorvastatin Toxicol. Lett. 2018 291 184 193 10.1016/j.toxlet.2018.04.016 29679711 · DOI
  76. [87]Irfan F. Karim S.I. Co-Prescription of Ciprofloxacin and Statins; a Dangerous Combination: Case Report J. Pak. Med. Assoc. 2020 70 1272 1274 10.5455/JPMA.29595 32799291 · DOI
  77. [88]Hennessy E. Adams C. Reen F.J. O’Gara F. Is There Potential for Repurposing Statins as Novel Antimicrobials? Antimicrob. Agents Chemother. 2016 60 5111 5121 10.1128/AAC.00192-16 27324773 PMC4997871 · DOI
  78. [89]Parihar S.P. Guler R. Brombacher F. Statins: A Viable Candidate for Host-Directed Therapy against Infectious Diseases Nat. Rev. Immunol. 2018 19 104 117 10.1038/s41577-018-0094-3 30487528 · DOI
  79. [90]Ko H.H.T. Lareu R.R. Dix B.R. Hughes J.D. Statins: Antimicrobial Resistance Breakers or Makers? PeerJ 2017 2017 e3952 10.7717/peerj.3952 29085751 PMC5659212 · DOI
  80. [91]Masadeh M. Mhaidat N. Alzoubi K. Al-azzam S. Alnasser Z. Antibacterial Activity of Statins: A Comparative Study of Atorvastatin, Simvastatin, and Rosuvastatin Ann. Clin. Microbiol. Antimicrob. 2012 11 13 10.1186/1476-0711-11-13 22564676 PMC3408379 · DOI
  81. [92]Basyoni M.M.A. Fouad S.A. Amer M.F. Amer A.F. Ismail D.I. Atorvastatin: In-Vivo Synergy with Metronidazole as Anti-Blastocystis Therapy Korean J. Parasitol. 2018 56 105 10.3347/kjp.2018.56.2.105 29742864 PMC5976012 · DOI
  82. [93]Morales-Alvarez M.C. Nephrotoxicity of Antimicrobials and Antibiotics Adv. Chronic Kidney Dis. 2020 27 31 37 10.1053/j.ackd.2019.08.001 32146999 · DOI
  83. [94]Niedrig D. Maechler S. Hoppe L. Corti N. Kovari H. Russmann S. Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care Hospital: Administration of Interacting Co-Medication and QT Prolongation Eur. J. Clin. Pharmacol. 2016 72 859 867 10.1007/s00228-016-2043-z 27023463 · DOI

Cited by

Sorted by citations

Authors
Spanakis, M., Alon-Ellenbogen, D., Ioannou, P., & Spernovasilis, N.
Affiliations
  • University of Crete (GR)
  • University of Nicosia (CY)
  • Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, 71110 Heraklion, Greece
  • Department of Infectious Diseases, German Oncology Center, 4108 Limassol, Cyprus
Corresponding author
Spernovasilis, Nikolaos
ORCID
Venue
Pharmacy
Publisher
MDPI AG
Published
2023-08-19
Volume
11
Issue
4
Pages
130
ISSN
2226-4787 (ISSN-L)
DOI
10.3390/pharmacy11040130
PMC
PMC10457919
OpenAlex
W4386030519
Cited by
3
References
2
Citations by year
2025: 2 · 2024: 1
FWCI
0.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
drug-drug interactions, antibiotics, lipid-modifying drugs, statins, macrolides, lipid-lowering therapy, antibiotic prescribing, acute bacterial infection, evidence-based prescribing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review